Secondary hyperparathyroidism happens when your parathyroid glands overproduce parathyroid hormone (PTH) in response to another condition, most commonly chronic kidney disease. Unlike primary hyperparathyroidism, where the glands themselves malfunction, secondary hyperparathyroidism is a reactive process: something else in the body drives calcium or phosphorus out of balance, and the parathyroid glands ramp up PTH production to compensate.
How the Parathyroid Glands Respond to Low Calcium
Your four parathyroid glands sit behind the thyroid in your neck. Their sole job is monitoring blood calcium levels and releasing PTH when calcium drops too low. PTH then pulls calcium from bones, tells the kidneys to hold onto calcium instead of excreting it, and boosts the activation of vitamin D so your intestines absorb more calcium from food.
This feedback loop normally keeps calcium in a tight range. But when something chronically suppresses calcium levels or blocks the glands from sensing calcium correctly, they don’t just release a little extra PTH. They begin producing PTH continuously. Over time, the gland cells actually multiply, enlarging the glands themselves. This overgrowth makes the problem harder to reverse because more cells means more hormone output, even if the original trigger improves. Drugs that mimic calcium at the gland’s sensor can slow this proliferation and even shrink gland size, which confirms that chronic low calcium is a direct driver of gland enlargement.
Chronic Kidney Disease: The Most Common Cause
The vast majority of secondary hyperparathyroidism cases trace back to chronic kidney disease (CKD). The mechanism unfolds in stages as kidney function declines, and it involves three interlocking problems: phosphorus buildup, vitamin D deficiency, and low calcium.
Healthy kidneys filter excess phosphorus out of the blood. As kidney filtration drops, phosphorus starts to accumulate. Early on, the body compensates. Bone cells release a hormone called FGF23 that forces each remaining kidney unit to excrete more phosphorus per cycle. PTH rises for the same reason. Together, FGF23 and PTH keep phosphorus levels looking normal on blood tests for a while, but the cost is that both hormones are now elevated. This compensatory phase can begin in early-stage CKD, well before a person feels sick.
The problem deepens because FGF23 suppresses the kidney’s ability to activate vitamin D. The kidneys are responsible for converting stored vitamin D into its active form, which is essential for absorbing calcium from food. As active vitamin D drops, less calcium enters the bloodstream from the gut, and blood calcium falls. Low calcium is a direct signal for even more PTH release. Studies show that vitamin D levels below 30 ng/mL are present in 71% of people with moderate CKD, 84% with more advanced disease, and 89% of those approaching kidney failure.
In advanced CKD, the compensatory system breaks down entirely. The kidneys can no longer excrete enough phosphorus regardless of how much FGF23 and PTH push them. Phosphorus levels rise visibly on lab work. Active vitamin D production drops further because high phosphorus itself blocks the enzyme that activates it. Calcium stays chronically low. At this point, PTH levels can reach several times the normal range, and the parathyroid glands may be significantly enlarged.
Vitamin D Deficiency Without Kidney Disease
You don’t need kidney disease to develop secondary hyperparathyroidism. Vitamin D deficiency alone can trigger it. Active vitamin D does two critical things that keep PTH in check: it promotes calcium absorption in the intestines, and it directly suppresses the gene that tells parathyroid cells to make PTH. When vitamin D is insufficient, both brakes come off simultaneously. Less calcium gets absorbed from food, and the parathyroid glands lose a chemical signal that would normally tell them to quiet down.
People at higher risk for vitamin D deficiency include those with limited sun exposure, darker skin, obesity (vitamin D gets sequestered in fat tissue), and older adults whose skin produces less vitamin D. In many of these cases, PTH levels normalize once vitamin D stores are replenished, particularly when blood levels reach at least 30 ng/mL.
Calcium Malabsorption and Bariatric Surgery
Any condition that prevents your gut from absorbing calcium properly can trigger secondary hyperparathyroidism, even if your diet and vitamin D levels are adequate. Celiac disease, inflammatory bowel disease, and other malabsorption syndromes fall into this category.
Bariatric surgery is a particularly well-documented cause. Around 70% of patients who undergo biliopancreatic diversion, a type of weight-loss surgery that reroutes a significant portion of the digestive tract, develop secondary hyperparathyroidism over the long term. Research into this group found that the problem isn’t always about vitamin D. Even among patients whose vitamin D levels were corrected to normal ranges, about half still had persistently elevated PTH because their individual ability to absorb calcium from the gut remained impaired. The risk worsens with age, likely because passive calcium absorption through the intestinal lining naturally declines over time.
Gastric bypass procedures carry similar risks, though typically at lower rates than biliopancreatic diversion, because less of the intestine is bypassed.
Low Dietary Calcium Intake
Sometimes the cause is straightforward: not enough calcium coming in through food. Secondary hyperparathyroidism can develop when calcium intake is chronically low, even when kidneys and vitamin D levels are normal. Blood calcium may sit in the low-normal range rather than being obviously deficient, which can make the diagnosis less obvious. In documented cases, supplementing with oral calcium (around 1,200 mg per day in divided doses) resolved the elevated PTH, confirming that inadequate intake was the driver.
This is more common in people who avoid dairy, follow restrictive diets, or have poor nutritional intake due to age or illness. Because blood calcium is so tightly regulated, your body will pull calcium from bones long before your blood levels drop below the lab’s reference range. That means PTH can be elevated and bone loss can be underway while standard calcium blood tests still look acceptable.
The Cascade That Makes It Worse Over Time
What makes secondary hyperparathyroidism particularly damaging is that the compensatory response itself causes harm. Chronically elevated PTH pulls calcium out of bones to maintain blood levels, gradually weakening the skeleton. This can lead to bone pain, increased fracture risk, and a condition called renal osteodystrophy in kidney disease patients, where bones become porous or abnormally soft.
High phosphorus levels compound the problem. When phosphorus and calcium are both elevated in the blood, they can form deposits in blood vessels, heart valves, and soft tissues. In severe cases, particularly in dialysis patients, calcium-phosphorus deposits in small blood vessels under the skin can cause painful, dangerous tissue damage.
The parathyroid glands themselves change structurally. Early on, all the cells in the gland grow larger (diffuse hyperplasia), and the condition responds well to correcting the underlying cause. Over years of sustained stimulation, clusters of cells begin multiplying independently (nodular hyperplasia). These nodules become less responsive to calcium and vitamin D signals, creating a situation where the glands essentially run on autopilot. At that stage, medical treatment becomes less effective, and surgical removal of some or all of the parathyroid tissue may become necessary.
Why Early Detection Matters
The underlying causes of secondary hyperparathyroidism, whether kidney disease, vitamin D deficiency, malabsorption, or dietary gaps, are all treatable. The challenge is that PTH can climb silently for years. People with CKD stage 3 or higher are typically monitored for rising PTH as part of routine bloodwork. Current guidelines recommend investigating when PTH levels are progressively rising or persistently above the lab’s normal upper limit, looking specifically for correctable factors like high phosphorus, low calcium, excessive dietary phosphorus, and vitamin D deficiency.
For people on dialysis, PTH levels are generally expected to run higher than normal, with clinical guidelines suggesting a target of roughly two to nine times the upper limit of normal. This reflects the reality that completely normalizing PTH in advanced kidney failure is neither practical nor necessarily beneficial, since over-suppression carries its own risks to bone health.
Outside of kidney disease, anyone with known malabsorption, a history of bariatric surgery, or risk factors for vitamin D deficiency benefits from periodic PTH and vitamin D testing. Catching the problem early, before the parathyroid glands undergo structural changes, makes it far more likely that correcting the root cause will bring PTH back to normal.